250602-53-0

Upstream product

• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 
• 250602-52-9 {4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}methanol 

Downstream Products

• 421558-31-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenylacetonitrile 
• 1027443-74-8 2-[(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-hexanoic acid ethyl ester 
• 250601-17-3 ethyl (Z)-3-methyl-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}butyroate 
• 250601-18-4 ethyl (E)-3-methyl-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}butyrate 
• 250601-20-8 ethyl (Z)-2-(4-bromophenyl)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}acetate 
• 1026737-57-4 2-[(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-3-phenyl-propionic acid ethyl ester 
• 250601-19-5 ethyl (E)-2-(4-bromophenyl)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}acetate 
• 250601-36-6 ethyl (Z)-2-(3-bromophenyl)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}acetate 
• 250601-16-2 ethyl (Z)-2-(4-methoxyphenyl)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}acetate 
• 1026622-55-8 [(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-(4-phenoxy-phenyl)-acetic acid ethyl ester 
• 250602-81-4 N-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxy}phtalimide 
• 675144-17-9 3-({4-[(2-phenyl-5-methyl-1,3-oxazol-4-yl)methoxy]benzyl}oxy)-1-phenyl-1H-pyrazole-4-carbaldehyde 
• 250601-04-8 (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutanoic acid 

Relevant academic research and scientific papers

BODY WEIGHT GAIN INHIBITORS

An agent for inhibiting body weight gain derived from a PPARγ agonist-like substance, which contains a PPARδ agonist-like substance, is useful for the treatment of diabetes and the like.

CRYSTALS OF AN OXYIMINOALKANOIC ACID DERIVATIVE AND THEIR USE AS ANTIDIABETICS

Crystals of (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutyric acid (provided that crystals having a melting point of 126° C. to 127° C. are excluded), which have an excellent anti-diabetic action.

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKAy mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (Z)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4- phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, p0.01) and plasma triglycelide levels (43%, p0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported.

Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents.

A series of 5-(4-alkoxyphenylalkyl)-1H-tetrazole derivatives, containing an oxazole-based group at the alkoxy moiety, was prepared and their antidiabetic effects were evaluated in two genetically obese and diabetic animal models, KKAy mice and Wistar fatt

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.